Main content

    Pancreatic Cancer Clinical Research

    CPMC Cancer Services

    Oncology / Cancer Clinical Trials Main Page | Adult Clinical Trials Main Page

    Further protocol information can be found on the links below at ClinicalTrials.gov


    Adjuvant Therapy  |  Metastatic Pancreatic Cancer  |  Non-Metastatic Pancreatic Cancer  |  Pancreatic Neuroendocrine Tumors


    Active Trials

    Adjuvant Therapy


    Currently there are no Clinical Research Studies for Adjuvant Therapy. Please check back at a later date as we are always adding new studies.
    Back to top


    Active Trials

    Metastatic Pancreatic Cancer

    Title: A Phase 2, Randomized, Multicenter Study of PEGPH20 (PEGylated Recombinant Human Hyaluronidase)Combined With Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Previously Untreated Pancreatic Cancer
    Description: PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Untreated Pancreatic Cancer (HALO-109-202)
    Investigator: Ari Baron, MD
    Eligibility: Subjects, 18 y/o and older, who have Histologically confirmed Stage IV pancreatic ductal adenocarcinoma w/ documented disseminated neoplasm to liver and /or lung. Must have archival or fresh tissue (block /slides) available pre-dose
    Status: Active and open to enrollment
    Contact: Laurel Brechtel, 415-600-1654, Email: BrechtLA@cpmcri.org about Study HALO-109-202

    Title: A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors
    Description: Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
    Investigator: NCI - National Cancer Institute
    Eligibility: Subjects, 18 y/o and older, who have histologically or pathologically confirmed locally unresectable or metastatic low or intermediate grade pancreatic neuroendocrine tumor, excluding small cell carcinoma
    Status: Active and open to enrollment
    Contact: Laurel Brechtel, 415-600-1654, Email: BrechtLA@cpmcri.org about Study ECOG E2211

    Title: A Randomized, Double-Blind, Phase 3 Study of the Janus Kinase (JAK) 1/2 Inhibitor, Ruxolitinib, or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy
    Description: This study is to determine the efficacy, based upon overall survival, of ruxolitinib added to capecitabine for the treatment of metastatic pancreatic cancer
    Investigator: Ari Baron, MD
    Eligibility: Male subjects 18 y/o and older with histologic or cytological diagnosis of adenocarcinoma of the prostate
    Status: Active and open to enrollment
    Contact: Laurel Brechtel, 415-600-1654, Email: BrechtLA@cpmcri.org about Study Incyte JANUS 1

    Back to top

    Active Trials

    Non-Metastatic Pancreatic Cancer

    Title: A Phase III Study of FOLFIRINOX With or Without HyperAcute®-Pancreas (Algenpantucel-L) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
    Description: Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
    Investigator: Ari Baron, MD
    Eligibility: Subjects 18 y/o and older with a diagnosis of pancreatic cancer
    Status: Active and open to enrollment
    Contact: Laurel Brechtel, 415-600-1654, Email: BrechtLA@cpmcri.org about Study NLG0505

    Back to top

    Active Trials

    Pancreatic Neuroendocrine Tumors

    Title: A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors
    Description: This randomized phase II trial studies how well giving temozolomide with or without capecitabine works in treating patients with advanced pancreatic neuroendocrine tumors
    Investigator: NCI - National Cancer Institute
    Eligibility: Subjects, 18 y/o and older, who have histologically or pathologically confirmed locally unresectable or metastatic low or intermediate grade pancreatic neuroendocrine tumor, excluding small cell carcinoma
    Status: Call site for study status
    Contact: Laurel Brechtel, 415-600-1654, Email: BrechtLA@cpmcri.org about Study ECOG E2211

    • updated December 2014

    Back to top